Literature DB >> 9089462

The epidemiology of Alzheimer disease in intellectual disability: results and recommendations from an international conference.

W Zigman1, N Schupf, M Haveman, W Silverman.   

Abstract

Among adults with intellectual disability, virtually everyone with Down's syndrome (DS) over the age of 40 years has neuropathology currently viewed to be consistent with a diagnosis of Alzheimer disease (AD), while other adults with intellectual disability without DS display an increased prevalence of Alzheimer-type neuropathology after they reach the age of 65. This paper presents the results of discussions by an epidemiology workgroup, formed at an international conference convened to discuss AD among people with intellectual disability, concerning: (1) the incidence and prevalence of clinical dementia in adults with intellectual disability; (2) risk factors for the development of AD in adults with intellectual disability; and (3) a minimum data set that would be of great utility for future research on AD in adults with intellectual disability.

Entities:  

Mesh:

Year:  1997        PMID: 9089462     DOI: 10.1111/j.1365-2788.1997.tb00679.x

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  15 in total

1.  Links between the pathology of Alzheimer's disease and vascular dementia.

Authors:  Marcin Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; Yong-sheng Li; David Quartermain; Karen Duff; Thomas Wisniewski
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

Review 2.  Prospects for improving brain function in individuals with Down syndrome.

Authors:  Alberto C S Costa; Jonah J Scott-McKean
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

3.  Alzheimer's Disease in Adults with Down Syndrome.

Authors:  Warren B Zigman; Darlynne A Devenny; Sharon J Krinsky-McHale; Edmund C Jenkins; Tiina K Urv; Jerzy Wegiel; Nicole Schupf; Wayne Silverman
Journal:  Int Rev Res Ment Retard       Date:  2008-01-01

4.  Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP.

Authors:  Eric Doran; David Keator; Elizabeth Head; Michael J Phelan; Ron Kim; Minodora Totoiu; Jorge R Barrio; Gary W Small; Steven G Potkin; Ira T Lott
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

5.  Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-β Burden in Down Syndrome.

Authors:  Patrick J Lao; Ben L Handen; Tobey J Betthauser; Iulia Mihaila; Sigan L Hartley; Annie D Cohen; Dana L Tudorascu; Peter D Bulova; Brian J Lopresti; Rameshwari V Tumuluru; Dhanabalan Murali; Chester A Mathis; Todd E Barnhart; Charles K Stone; Julie C Price; Darlynne A Devenny; Sterling C Johnson; William E Klunk; Bradley T Christian
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 6.  On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome.

Authors:  Alberto C S Costa
Journal:  Dev Neurosci       Date:  2011-09-02       Impact factor: 2.984

7.  Stability and change in health, functional abilities, and behavior problems among adults with and without Down syndrome.

Authors:  Anna J Esbensen; Marsha Mailick Seltzer; Marty Wyngaarden Krauss
Journal:  Am J Ment Retard       Date:  2008-07

8.  Microbleeds and Cerebral Amyloid Angiopathy in the Brains of People with Down Syndrome with Alzheimer's Disease.

Authors:  Alex M Helman; Morgan Siever; Katie L McCarty; Ira T Lott; Eric Doran; Erin L Abner; Frederick A Schmitt; Elizabeth Head
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

9.  Differentiating Aging Among Adults With Down Syndrome and Comorbid Dementia or Psychopathology.

Authors:  Anna J Esbensen; Emily Boshkoff Johnson; Joseph L Amaral; Christine M Tan; Ryan Macks
Journal:  Am J Intellect Dev Disabil       Date:  2016-01

Review 10.  The impact of aging on eating, drinking, and swallowing function in people with Down's syndrome.

Authors:  Tracy Lazenby
Journal:  Dysphagia       Date:  2008-03       Impact factor: 3.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.